The global NAFLD epidemic
- PMID: 24042449
- DOI: 10.1038/nrgastro.2013.171
The global NAFLD epidemic
Abstract
NAFLD is a clinical syndrome characterized by predominant macrovesicular steatosis of the liver. The clinical and histological phenotypes of NAFLD extend from a nonalcoholic fatty liver to NASH. Although the prevalence of NAFLD is increasing globally, and it is set to become the predominant cause of chronic liver disease in many parts of the world, the epidemiology and demographic characteristics of NAFLD vary worldwide. Indeed, the condition is associated with obesity and insulin resistance in most cases in the Western world, but the disease manifests at a lower BMI in Asian countries and many patients do not seem to have insulin resistance as determined using conventional methods. The similarities and differences in the epidemiology of NAFLD in different regions of the world are discussed and the potential role of genetics and insulin resistance in disease progression is also presented.
Similar articles
-
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021. Epub 2019 Jul 4. J Hepatol. 2019. PMID: 31279902
-
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.J Clin Endocrinol Metab. 2015 Jun;100(6):2231-8. doi: 10.1210/jc.2015-1966. Epub 2015 Apr 17. J Clin Endocrinol Metab. 2015. PMID: 25885947 Free PMC article.
-
Fructose as a key player in the development of fatty liver disease.World J Gastroenterol. 2013 Feb 28;19(8):1166-72. doi: 10.3748/wjg.v19.i8.1166. World J Gastroenterol. 2013. PMID: 23482247 Free PMC article. Review.
-
Epidemiology and natural history of patients with NAFLD.Curr Pharm Des. 2013;19(29):5169-76. doi: 10.2174/13816128113199990336. Curr Pharm Des. 2013. PMID: 23394091 Review.
-
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.Adv Ther. 2009 Oct;26(10):893-907. doi: 10.1007/s12325-009-0072-z. Epub 2009 Nov 16. Adv Ther. 2009. PMID: 19921118 Free PMC article. Review.
Cited by
-
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1(Suppl 1):S41-S51. doi: 10.1111/apt.17752. Aliment Pharmacol Ther. 2024. PMID: 38813822 Review.
-
Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis.World J Pediatr. 2024 May 21. doi: 10.1007/s12519-024-00814-1. Online ahead of print. World J Pediatr. 2024. PMID: 38771552 Review.
-
Sylimarin Versus Essential Phospholipids in Metabolic Associated Steatotic Liver Disease (MASLD) - A Prospective Comparative Randomized Trial.Maedica (Bucur). 2024 Mar;19(1):9-16. doi: 10.26574/maedica.2024.19.11.9. Maedica (Bucur). 2024. PMID: 38736928 Free PMC article.
-
Risk Factors for Non-Adherence to Medication for Liver Transplant Patients: An Umbrella Review.J Clin Med. 2024 Apr 18;13(8):2348. doi: 10.3390/jcm13082348. J Clin Med. 2024. PMID: 38673620 Free PMC article. Review.
-
Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression.Biomolecules. 2024 Mar 27;14(4):404. doi: 10.3390/biom14040404. Biomolecules. 2024. PMID: 38672422 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical